logo
Dirty habit millions admit to daily linked to 20x higher colon cancer death rate, says shock study

Dirty habit millions admit to daily linked to 20x higher colon cancer death rate, says shock study

Daily Mail​29-04-2025
People who smoke weed are up to 20 times more likely to die from colon cancer, a shock study suggests.
The study appears to blow the idea that cannabis can treat cancer - a myth that has prevailed in pro-weed circles for decades.
Researchers in California looked through health records from more than 1,000 people - all of whom had colon cancer.
They then compared cannabis users to non-users.
They found colon cancer patients with a history of using cannabis every day or nearly every day had a 56 percent chance of dying within five years.
This was an 11-fold difference compared to people who never used marijuana.
And people formally diagnosed with cannabis use disorder - cannabis addiction - within months of being struck by colon cancer were 24 times more likely to die in five years compared to their peers.
The experts, from the University of California San Diego, believe THC, the active ingredient in cannabis that causes hallucinogenic effects, may cause inflammation in the colon, which causes cancer cells to grow.
THC may also block the production of disease-fighting T cells, which normally destroy cancer cells.
Additionally, cannabis use disorder may lead to depression and anxiety, making patients less likely to commit to cancer treatments.
However, just three percent of participants had cannabis use disorder, and it's unclear what stage their cancers were.
The researchers said more studies are needed to understand how exactly cannabis addiction may increase the risk of colon cancer death.
About 18million Americans use marijuana daily or nearly everyday, and about one in three are addicted to the substance.
CUD is defined as using cannabis every day or nearly every day to the point where it negatively impacts a user's life, such as making it difficult to hold down a job.
Dr Raphael Cuomo, associate professor in the Department of Anesthesiology at UC San Diego School of Medicine, said: 'This study adds to a growing body of evidence suggesting that heavy cannabis use may have underrecognized impacts on the immune system, mental health and treatment behaviors — all of which could influence cancer outcomes.'
Though the findings seem surprising, they come from the same institution that published a groundbreaking study last week tying the colon cancer epidemic in young Americans to childhood exposure to the common bacteria E. coli.
This would put nearly 100,000 Americans at risk.
According to the latest data, early-onset colon cancer diagnoses in the US are expected to rise by 90 percent in people 20 to 34 years old between 2010 and 2030.
In teens, rates have surged 500 percent since the early 2000s.
Cannabis use is also on the rise, largely due to recent decriminalization across the US.
From 1992 to 2022, for example, daily and near-daily use has seen a 15-fold rise.
The new study, published Monday in the Annals of Epidemiology, look at medical records from 1,088 colon cancer patients in the University of California Health system between 2012 and 2024.
Of those, 34 were also diagnosed with cannabis use disorder.
The average age at colon cancer diagnosis was 59. On average, patients with CUD were diagnosed four months before learning they also had colon cancer.
After accounting for other health factors like age, gender and disease severity, the researchers found the risk of dying within five years of diagnosis for patients with an active cannabis addiction was 56 percent compared to five percent in non users.
Additionally, patients diagnosed with CUD before colon cancer had a 24-fold increased risk of death within five years of diagnosis.
The researchers wrote: 'The results of this study indicate that a history of cannabis use disorder prior to colon cancer diagnosis is independently associated with an increased risk of mortality, even after adjusting for demographic and clinical confounders.'
The experts are unsure exactly what caused the surge in mortality rate, but based on past research, they suggested THC could lead to harmful inflammation in the colon.
This inflammation suppresses T cells, a type of white blood cell meant to kill cancer cells.
Inflammation also damages colon tissue over time, causing cells to rapidly form to help repair the destruction. The faster cells form, the more likely they are to divide and mutate into cancer cells.
Additionally, cannabis may lead to mental health consequences.
Dr Cuomo said: 'High cannabis use is often associated with depression, anxiety and other challenges that may compromise a patient's ability to engage fully with cancer treatment.'
The study directly contradicts some earlier research which has suggested some compounds in cannabis may inhibit cancer cell growth.
A 2019 study from Penn State researchers of 370 synthetic cannabis compounds, for example, found 10 of them slowed the growth of seven forms of colon cancer.
However, those researchers cautioned the mechanism behind this is unclear.
Dr Cuomo said further research is needed to understand the mechanisms of cannabis addiction and colorectal cancer.
He also emphasized the findings don't mean cannabis users have to quit entirely.
He sadi: 'This isn't about vilifying cannabis. It's about understanding the full range of its impacts, especially for people facing serious illnesses.
'We hope these findings encourage more research — and more nuanced conversations — about how cannabis interacts with cancer biology and care.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hundreds hit with food poisoning in Indonesia after eating free meals from president's flagship program
Hundreds hit with food poisoning in Indonesia after eating free meals from president's flagship program

The Guardian

time2 minutes ago

  • The Guardian

Hundreds hit with food poisoning in Indonesia after eating free meals from president's flagship program

More than 360 people fell ill in the Indonesian town of Sragen in Central Java after consuming school lunches, according to officials, in the largest food poisoning case to hit president Prabowo Subianto's flagship free meals programme to date. Since its launch in January, the free school meals programme has been marred by mass food poisoning cases across the archipelago, affecting over 1,000 people. Sragen government chief Sigit Pamungkas told Reuters 365 people fell ill and a food sample had been sent to a lab for testing. The government said it would pay for any medical treatment if needed. One student at a local middle school told Reuters he was woken at night by sharp pain in his stomach. He had a headache and diarrhoea, which he realised had been caused by food poisoning after seeing schoolmates' social media posts complaining the same. The likely contaminated lunch was turmeric rice, omelette ribbons, fried tempeh, cucumber and lettuce salad, sliced apple and a box of milk, cooked in a central kitchen and distributed to several schools. 'We have asked to temporarily stop the food distribution from that kitchen until the lab results are back,' Sigit said. The government's national nutrition agency, which oversees the programme, has raised the standards of kitchen operations and delivery in the aftermath of previous food poisoning cases, its chief Dadan Hindayana told Reuters. The multi-billion dollar policy was a centrepiece of Prabowo's election campaign and the former general said the programme would improve participants quality of life and boost economic growth. The free meals programme has been rapidly expanded to over 15 million recipients so far. Authorities plan to reach 83 million people by year-end, budgeting a total cost of 171 trillion rupiah ($10.62bn) this year. In January, at least 190 kitchens run by third-party catering services opened nationwide, including some run by military bases, to produce the meals. In a food poisoning case in a city in West Java in May, more than 200 students fell ill and a lab found the food was contaminated with Salmonella and E. coli bacteria, according to media reports.

Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer
Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer

Daily Mirror

time3 hours ago

  • Daily Mirror

Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer

Eli Lilly is increasing the UK price of its weight-loss drug Mounjaro Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages expected to see a staggering 170 percent increase starting from September. ‌ The pharmaceutical giant has justified the price surge as an effort to "address pricing inconsistencies compared with other developed countries, including in Europe" and to ensure equitable global contributions towards funding medical research. ‌ The sharpest rise will affect the month's supply of the drug's highest doses, which will soar from £122 to £330. Smaller doses will experience increases ranging from 45 to 138 percent. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. ‌ Despite these changes, Lilly has assured that the NHS will not be affected by the new list prices, pledging to maintain the current rates to preserve uninterrupted patient access. Private healthcare providers, who also offer the medication, will face the new prices but have the option to negotiate confidential discounts directly with Eli Lilly. This development occurs amidst political debates in the US, where ex-president Donald Trump has lambasted what he deems "foreign freeloaders" for enjoying lower pharmaceutical costs while Americans bear much higher expenses. In one address, he highlighted obesity treatments, recounting how a friend in London acquired the "fat shot drug" at a fraction of the US cost, reports the Daily Record. Research from the Rand Corporation indicates that drug prices in the US are typically almost triple those in several other advanced nations. The pharmaceutical sector has been mobilising to combat the potential danger of a "most favoured nation" strategy, which could tie American pricing to international rates. ‌ Lilly highlighted that the UK was amongst the earliest markets to receive Mounjaro and emphasised that its initial focus had been on delivering the medication to diabetic patients swiftly. "At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation," the firm stated. Talks between pharmaceutical companies and the UK Government regarding NHS drug costs have grown increasingly fraught, with deliberations about modifications to a clawback levy on pharmaceutical sales extending well beyond agreed timelines. ‌ The Government's latest proposals featured plans to increase spending on medications, though industry chiefs voiced exasperation over the absence of specifics or clarity regarding whether this would involve purchasing additional medicines or paying elevated prices for current treatments. The National Institute for Health and Care Excellence (NICE) has endorsed Mounjaro for as many as 3.4 million individuals across England. Nevertheless, worries about cost-effectiveness resulted in an arrangement for a staged introduction, beginning with approximately 250,000 patients presenting the most urgent clinical requirements during the initial three years. NHS England has assured that the forthcoming price alterations will not impact the provision of the medication to qualified patients suffering from obesity or diabetes. "Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers," NHS England stated. The adjustments bring the UK's pricing more in line with the European mean, occurring amidst a period when drug manufacturers are acutely aware of how varying international prices might influence upcoming policy choices in the US.

NHS Fife carrying out equality review over trans staff changing room use after breaking law
NHS Fife carrying out equality review over trans staff changing room use after breaking law

The Courier

time5 hours ago

  • The Courier

NHS Fife carrying out equality review over trans staff changing room use after breaking law

NHS Fife has launched an urgent equality review into transgender staff accessing single-sex changing rooms, after admitting it broke the law by failing to carry one out previously. The health board says it will conduct the review by September 30 after tough criticism from the UK's equalities regulator, the Equality and Human Rights Commission (EHRC). The watchdog first wrote to NHS Fife on February 21 following coverage of the employment tribunal brought by nurse Sandie Peggie – who is suing the health board and transgender A&E medic Dr Beth Upton. A&E nurse Ms Peggie says she was discriminated against and harassed by being forced to share a changing room with Dr Upton, who was born male, at Victoria Hospital in Kirkcaldy. The EHRC initially reminded NHS Fife of their obligations under the Equality Act, including the provision of single-sex facilities for staff. But the health board admitted it had not completed an impact assessment over the use of single-sex toilets and changing rooms by transgender staff. Following this admission the regulator directed NHS Fife to take 'corrective action' to ensure it was in compliance with the law. It pointed out public bodies have 'a duty to assess and review proposed new or revised policies or practices'. On July 23, the EHRC says NHS Fife assured them it has conducted a full review and audit of changing, toilet and locker room facilities. It says the health board has also committed to ensuring there will be 'no delay in progressing all the compliance actions' it was directed to undertake. Baroness Kishwer Falkner, chairwoman of the EHRC, said undertaking impact assessments and publishing the results are legal requirements. She added: 'We believe NHS Fife failed to meet these requirements and told them to carry one out immediately. 'NHS Fife has now confirmed that it has commissioned an equality impact assessment and anticipates it will be published by September 30. 'Since we first wrote to NHS Fife, the Supreme Court ruled on the definition of 'sex' in the Equality Act. 'The EHRC has been clear that all duty-bearers should be following the law, as set out in the judgment handed down on April 16. 'NHS Fife has assured us that it is following our advice to review the implications of the judgment for its policies and procedures, seeking specialist legal advice where necessary.' She said the corrective actions are essential for NHS Fife to protect staff from discrimination and harassment on the basis of sex, religion or belief, and gender reassignment. 'We will continue to engage with NHS Fife and monitor its progress and the outcome of the measures it has committed to taking, to ensure compliance with the Equality Act and Public Sector Equality Duty,' she added. An NHS Fife spokesman welcomed the EHRC's engagement. He said: 'A comprehensive review and audit of our facilities has been completed, and an equality impact assessment is underway. This will be concluded and published by September 30. 'Our priority is to ensure that all NHS Fife policies and practices protect the rights of our staff and comply fully with equality legislation.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store